CVS Group plc Exercise of Options and Total Voting Rights (0614B)

TIDMCVSG

RNS Number : 0614B

CVS Group plc

31 May 2023

CVS Group plc

("CVS" or the "Company")

Exercise of Options and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services, confirms that certain employees have exercised options during May under the CVS Group 2019 SAYE Plan (2019/2023) totalling 10,939 ordinary shares of 0.2 pence each ("Ordinary Shares"). One employee also exercised options under the CVS Group Long Term Incentive Plan ("LTIP 13") over 3,704 new Ordinary Shares.

The sum of 10,939 new Ordinary Shares were issued to satisfy the balance of Ordinary Shares arising from the SAYE Exercise. Admission of the 10,939 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 30 December 2021. Additionally, 3,704 new Ordinary Shares were issued to satisfy the balance of Ordinary Shares arising from the LTIP 13 Exercise. Admission of the 3,704 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 15 May 2023.

Following the issue of these new Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, the Company has a total issued share capital of 71,410,444 Ordinary Shares, each carrying one voting right. The Company holds no Ordinary Shares in treasury and the total number of voting rights is therefore 71,410,444.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group plc via Camarco

Richard Fairman, CEO

Jenny Farrer, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

Berenberg (Joint Broker)

+44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR)

Geoffrey Pelham-Lane

+44 (0)7733 124 226

Ginny Pulbrook

+44 (0)7961 315 138

About CVS Group plc ( www.cvsukltd.co.uk )

CVS Group is an AIM-quoted fully-integrated provider of veterinary services in the UK, with practices in the Netherlands and the Republic of Ireland. CVS is focused on providing high quality clinical services to its customers and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group has c.500 veterinary practices across its three markets, including eight specialist referral hospitals and 37 dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices), Buying Groups and the Group's online retail business ("Animed Direct").

The Group employs c.8,500 personnel, including c.2,200 veterinary surgeons and c.3,100 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEBSGDUCBXDGXG

(END) Dow Jones Newswires

May 31, 2023 02:00 ET (06:00 GMT)

CVS (AQSE:CVSG.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024